Key result
Medical and surgical therapies targeting nonalloimmune factors like infection and reflux require further evaluation in randomized-controlled trials to manage post-lung transplant bronchiolitis obliterans syndrome.
Why the study?
Do surgical and nonsurgical treatments targeting nonalloimmune factors (infection, reflux/aspiration) prevent bronchiolitis obliterans syndrome in lung transplant recipients?
Do surgical and nonsurgical treatments targeting nonalloimmune factors (infection, reflux/aspiration) prevent bronchiolitis obliterans syndrome in lung transplant recipients?
Answers are grounded in this paper and cite their sources.
Nonalloimmune factors such as infection and reflux/aspiration contribute to allograft injury and bronchiolitis obliterans syndrome in lung transplant recipients, warranting further investigation into targeted therapies.
Chronic allograft dysfunction, manifesting as bronchiolitis obliterans syndrome (BOS), is the major cause of morbidity and mortality in human lung transplant recipients. While alloimmunity has a definite role, there is increasing interest in overall allograft injury and subsequent inflammation and remodeling. This review deals with nonalloimmune factors that may potentiate alloimmune injury. We discuss infection and reflux/aspiration as examples of allograft injury, which may lead to chronic loss of graft function and BOS. Surgical and nonsurgical treatments aimed at preventing these insults and improving survival are considered. The need for further evidence, including randomized-controlled trials, to evaluate the role of medical and surgical therapies is emphasized by the current literature.
No takes yet. Share an insight, caveat, or question.
Robertson et al. (2009) conducted a review in Post-Lung Transplant Bronchiolitis Obliterans Syndrome. Medical and surgical therapies targeting allograft injury and inflammation was evaluated. Medical and surgical therapies targeting nonalloimmune factors like infection and reflux require further evaluation in randomized-controlled trials to manage post-lung transplant bronchiolitis obliterans syndrome.
Synapse has enriched 10 related papers. Consider them for comparative context: